Outcome of transarterial chemoembolization in Egyptian patients with hepatocellular carcinoma and branch portal vein thrombosis
- 94 Downloads
Portal vein tumor thrombosis (PVTT) is a common complication in hepatocellular carcinoma (HCC) and it was considered a relative contraindication for transarterial chemoembolization (TACE) by many centers. This study aimed to assess the outcomes after TACE in patients with branch PVT regarding Child classification, radiological response, and 1-year survival.
Thirty HCC patients (24 male, 6 females) Child A cirrhotics with branch PVT underwent TACE. Follow up was done at 1, 3, 6, and 12 months after first TACE. All patients underwent laboratory investigations including liver function tests to assess deterioration in liver functions and triphasic spiral computed tomography to assess radiological response according to modified response evaluation criteria in solid tumors (mRECIST) criteria, and survival analysis was recorded.
TACE succeeded to achieve disease control in 93.3%, 86.3%, 57.7%, and 44.4% of patients after 1, 3, 6, and 12 months, respectively. Post-TACE liver decompensation occurred in the form of ascites in 30%, jaundice in 10%, and hepatic encephalopathy in 3.3% within 1 month of TACE. One month survival after TACE was 100%, 3 months was 96.6%, 6 months was 86.6%, and 1-year survival was 60%. Mean overall survival of the included patients was 17 months (SE = 1.59).
TACE seems an alternative option for patients with unrespectable HCC with portal vein thrombosis in patients with good liver function tests.
KeywordsHepatocellular carcinoma Portal vein thrombosis Transarterial chemoembolization
Compliance with ethical standards
Conflict of interest
HA, MKS, IFM, MS, HA, AS, SS, and AEl-D declare that they have no conflict of interest.
The study was approved by the Research and Ethics Committee of Ain Shams University, in accordance with local research governance requirements; the trial was registered with the federal clearing house for randomized trials on the ClinicalTrials.gov (NCT03007212).
- 1.IARC: preventable exposures associated with human cancers. J Natl Cancer Inst 2011; 103:1–14.Google Scholar